Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis

International Journal of Infectious Diseases

Volumn 49, Issue , 2016, Pages 129-133

  Badawi, Alaa ^a   Ryoo, Seung Gwan ^b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cardiovascular diseases; Diabetes mellitus; Middle East respiratory syndrome coronavirus (MERS CoV); Obesity; Systematic review

Indexed keywords

CYTOKINE;

CARDIOVASCULAR DISEASE; CLINICAL FEATURE; COMORBIDITY; CORONARY ARTERY DISEASE; COUGHING; DEMOGRAPHY; DIABETES MELLITUS; DOWN REGULATION; DYSPNEA; FEVER; FRANCE; GERMANY; HUMAN; HUMORAL IMMUNITY; HYPERTENSION; INCIDENCE; INNATE IMMUNITY; ITALY; JORDAN; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; OBESITY; PREVALENCE; SAUDI ARABIA; SEX RATIO; SHORT SURVEY; SORE THROAT; SYSTEMATIC REVIEW; TUNISIA; UNITED KINGDOM; CORONAVIRUS INFECTIONS; ISOLATION AND PURIFICATION; MALE; META ANALYSIS;

COMORBIDITY; CORONAVIRUS INFECTIONS; HUMANS; MALE; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; PREVALENCE;

EID: 84982085167     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2016.06.015     Document Type: Short Survey

References (34)

1. 1 The, W.H.O., Research Group, MERS-CoV., State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. PLoS Curr, 2013, 1, 10.1371/currents.outbreaks.0bf719e352e7478f8ad85fa30127ddb8.
2. 2 Assiri, A., Abedi, G.R., Saeed, A.A.B., Abdalla, M.A., al-Masry, M., Choudhry, A.J., et al. Multifacility outbreak of Middle East respiratory syndrome in Taif. Saudi Arabia. Emerg Infect Dis 22 (2016), 32–40.
3. 3 Assiri, A., McGeer, A., Perl, T.M., Price, C.S., Al-Rabeeah, A.A., Cummings, D.A., et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 369 (2013), 407–416.
4. 4 Memish, Z.A., Zumla, A.I., Assiri, A., Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med 369 (2013), 884–886.
5. 5 Memish, Z.A., Cotton, M., Watson, S.J., Kellam, P., Zumla, A., Alhakeem, R.F., et al. Community case cluster of Middle East respiratory syndrome coronavirus in Hafr Al-Batin. Kingdom of Saudi Arabia: a descriptive genomic study. Int J Infect Dis 23 (2014), 63–68.
6. 6 Arabi, Y.M., Arifi, A.A., Kalkhy, H.H., Najm, H., Aldawwod, A.S., Ghabashi, A., et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 160 (2014), 389–397.
7. 7 Assiri, A., Al-Tawfiq, J.A., Al-Rabeeah, A.A., Al-Rabiah, F.A., Al-Hajjar, S., Al-Barrak, A., et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 13 (2013), 752–761.
8. 8 Noorwali, A.A., Turkistani, A.M., Asiri, S.I., Trabulsi, F.A., Alwafi, O.M., Alzahrani, S.H., et al. Descriptive epidemiology and characteristics of confirmed cases of Middle East respiratory syndrome coronavirus infection in the Makkah Region of Saudi Arabia. March to June 2014. Ann Saudi Med 35 (2015), 203–209.
9. 9 Al-Tawfiq, J.A., Hinedi, K., Ghandour, J., Khairalla, H., Musleh, S., Ujayli, A., et al. Middle East respiratory syndrome coronavirus: a case–control study of hospitalized patients. Clin Infect Dis 59 (2014), 160–165.
10. 10 Shalhoub, S., Farahat, F., Al-Jiffri, A., Simhairi, R., Shamma, O., Siddiqi, N., et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. Antimicrob Chemother 70 (2015), 2129–2132.
11. 11 Alraddadi, B.M., Watson, J.T., Almarashi, A., Abedi, G.R., Turkistani, A., Sadran, M., et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans. Saudi Arabia, 2014. Emerg Infect Dis 22 (2016), 49–55.
12. 12 Al-Tawfiq, J.A., Momattin, H., Dib, J., Memish, Z.A., Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 20 (2014), 42–46.
13. 13 Higgins, J.P., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558, 10.1002/sim.1186.
14. 14 Wang, C., Yu, E., Xu, B., Wang, W., Li, L., Zhang, W., et al. Epidemiological and clinical characteristics of the outbreak of 2009 pandemic influenza A (H1N1) at a middle school in Luoyang. China. Public Health 126 (2012), 289–294.
15. 15 Mertz, D., Kim, T.H., Johnstone, J., Lam, P.P., Science, M., Kuster, S.P., et al. Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis. BMJ, 347, 2013, f5061.
16. 16 Al-Soub, H., Ibrahim, A.S., Al-Maslamani, M., Al-Khal, A.L., Shaath, S., Hamza, N.A., Epidemiology, risk factors, clinical features, and outcome of adult patients with severe pandemic A/H1N1/2009 influenza in Qatar: a retrospective study. Infect Dis Clin Pract 22 (2014), 339–343.
17. 17 Kusznierz, G., Uboldi, A., Sosa, G., Torales, S., Colombo, J., Moyano, C., et al. Clinical features of the hospitalized patients with 2009 pandemic influenza A (H1N1) in Santa Fe. Argentina. Influenza Other Respir Viruses 7 (2013), 410–417.
18. 18 Suryaprasad, A., Redd, J.T., Hancock, K., Branch, A., Steward-Clark, E., Katz, J.M., et al. Severe acute respiratory infections caused by 2009 pandemic influenza A (H1N1) among American Indians—southwestern United States, May 1–July 21, 2009. Influenza Other Respir Viruses 7 (2013), 1361–1369.
19. 19 Koegelenberg, C.F., Irusen, E.M., Cooper, R., Diacon, A.H., Taljaard, J.J., Mowlana, A., et al. High mortality from respiratory failure secondary to swine-origin influenza A (H1N1) in South Africa. QJM 103 (2010), 319–325.
20. 20 Odegaard, J.I., Chawla, A., Connecting type 1 and type 2 diabetes through innate immunity. Cold Spring Harbor Perspect Med, 2, 2012, a007724, 10.1101/cshperspect.a007724.
21. 21 Htun, N.S., Odermatt, P., Eze, I.C., Boillat-Blanco, N., D'Acremont, V., Probst-Hensch, N., Is diabetes a risk factor for a severe clinical presentation of dengue?. Review and meta-analysis. PLoS Negl Trop Dis, 9, 2015, e0003741, 10.1371/journal.pntd.0003741.
22. 22 Limonta, D., Torres, G., Capo, V., Guzman, M.G., Apoptosis, vascular leakage and increased risk of severe dengue in a type 2 diabetes mellitus patient. Diabetes Vasc Dis Res 2 (2008), 213–214.
23. 23 Dharmashankar, K., Widlansky, M.E., Vascular endothelial function and hypertension: insights and directions. Curr Hypertens Rep 12 (2010), 448–455.
24. 24 Toledo, J., George, L., Martinez, E., Lazaro, A., Han, W.W., Coelho, G.E., et al. Relevance of non-communicable comorbidities for the development of the severe forms of dengue: a systematic literature review. PLoS Negl Trop Dis, 10, 2016, e0004284, 10.1371/journal.pntd.0004284.
25. 25 Berger, A., Th1 and Th2 responses: what are they?. BMJ, 321, 2000, 424.
26. 26 Dooley, K.E., Chaisson, R.E., Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 9 (2009), 737–746.
27. 27 Akbar, D.H., Bacterial pneumonia: comparison between diabetics and non-diabetics. Acta Diabetol 38 (2001), 77–82.
28. 28 Alhyas, L., McKay, A., Majeed, A., Prevalence of type 2 diabetes in the states of the co-operation council for the Arab States of the Gulf: a systematic review. PLoS One, 7, 2012, e40948.
29. 29 International Diabetes Federation. IDF diabetes atlas: Middle East and North Africa. 6th ed. IDF; 2015. Available at: https://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf.(accessed May 18, 2016).
30. 30 Mokdad, A.H., Jaber, S., Abdel Aziz, M.I., AlBuhairan, F., AlGhaithi, A., AlHamad, N.M., et al. Burden of disease, injuries, and risk factors in the Arab World 1990-2010. Lancet 383 (2014), 309–920, 10.1016/S0140-6736(13)62189-3.
31. 31 Burney, L.E., Influenza immunization: statement. Public Health Rep, 75, 1960, 944.
32. 32 Fiore, A.E., Uyeki, T.M., Broder, K., Finelli, L., Euler, G.L., Singleton, J.A., et al. the Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 59 (2010), 1–62.
33. 33 Remschmidt, C., Wichmann, O., Harder, T., Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysis. BMC Med, 13, 2015, 53, 10.1186/s12916-015-0295-6.
34. 34 Remschmidt, C., Wichmann, O., Harder, T., Influenza vaccination in patients with end-stage renal disease: systematic review and assessment of quality of evidence related to vaccine efficacy, effectiveness, and safety. BMC Med, 12, 2014, 244, 10.1186/s12916-014-0244-9.